Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Obumneke Ugbor

Physician Assistant Mesa, AZ Physician Assistant

NPI 1992373906 CMS profile 11174876

1910 S Stapley Dr Ste 209, Mesa, AZ 85204

Open in the dashboard

General payments

$4,669

236 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Obumneke Ugbor of Mesa, AZ is reported in the CMS Open Payments database as having received $4,669 across 236 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $535 23
2024 General $2,028 100
2023 General $1,729 95
2022 General $377 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Obumneke Ugbor
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Obumneke Ugbor were reported at $535. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Obumneke Ugbor Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $377 $155 $48–$522 $149
2023 $1,729 $167 $52–$557 $160
2024 $2,028 $178 $55–$600 $164
2025 $535 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,075 69 payments
  2. ITI, Inc. $779 29 payments
  3. Teva Pharmaceuticals USA, Inc. $681 31 payments
  4. Otsuka America Pharmaceutical, Inc. $553 30 payments
  5. Lundbeck LLC $464 23 payments
  6. Janssen Pharmaceuticals, Inc $423 25 payments
  7. Axsome Therapeutics, Inc. $329 10 payments
  8. Alkermes, Inc. $84 4 payments
  9. Idorsia Pharmaceuticals US Inc $76 5 payments
  10. Neuronetics, Inc. $49 2 payments
  11. Other $155 8 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,555 234 payments
  2. Education $114 2 payments
Products named General payments · program years 2022–2025
  1. VRAYLAR Neuroscience $867 61 payments
  2. CAPLYTA $703 26 payments
  3. UZEDY $579 30 payments
  4. REXULTI Psychiatry $521 28 payments
  5. REXULTI Psychiatry $441 22 payments
  6. Auvelity $329 10 payments
  7. ABILIFY MAINTENA $326 18 payments
  8. SPRAVATO $311 17 payments
  9. VRAYLAR Neuroscience $208 8 payments
  10. INVEGA SUSTENNA $112 8 payments
  11. Other $493 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

236 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record